MESO
- Mesoblast Limited
()
Overview
Company Summary
Mesoblast Limited (MESO) is a global leader in developing innovative cell-based medicines. The company specializes in utilizing Mesenchymal Precursor Cells (MPCs), which are derived from adult bone marrow, to develop and commercialize innovative regenerative therapies for various diseases.
Mesoblast focuses on three key areas:
1. Immunologic and Inflammatory Diseases: The company develops therapies targeting conditions where the immune system plays a significant role, such as graft versus host disease (GVHD), acute respiratory distress syndrome (ARDS), and rheumatoid arthritis. Mesoblast's MPC-based products modulate the immune response, reducing inflammation and promoting tissue repair.
2. Cardiovascular Diseases: Mesoblast is involved in the development of regenerative therapies for cardiovascular conditions, including chronic heart failure and chronic myocardial ischemia. The company's products aim to enhance heart function and promote the formation of new blood vessels, thereby improving circulation and restoring damaged cardiac tissue.
3. Spinal and Musculoskeletal Disorders: Another area of focus for Mesoblast is the development of therapies for disorders of the spine and musculoskeletal system. This includes conditions like degenerative disc disease and lumbar disc herniation. The company's MPC-based therapies aim to reduce pain and inflammation, while also promoting tissue repair and regeneration.
Mesoblast utilizes advanced technology and scientific expertise to harness the potential of cell-based therapies. They have a robust portfolio of product candidates at various stages of development and collaborate with academic institutions, research organizations, and commercial partners to advance their therapies through clinical trials and ultimately to market.
By leveraging their knowledge in regenerative medicine, Mesoblast aims to transform the treatment landscape for patients suffering from a range of diseases and improve their quality of life.